Neurocrine Biosciences
NBIX
#1395
Rank
A$19.56 B
Marketcap
$193.20
Share price
0.52%
Change (1 day)
13.90%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2024 (TTM): A$0.97 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are A$2.24 Billion. In 2023 the company made an earning of A$0.55 Billion, an increase over its 2022 earnings that were of A$0.33 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) A$0.97 B75.64%
2023 A$0.55 B62.85%
2022 A$0.33 B73.74%
2021 A$0.19 B-8.82%
2020 A$0.21 B77.78%
2019 A$0.12 B49.83%
2018 A$80.52 M-142.57%
2017 -A$0.19 Billion-14.73%
2016 -A$0.23 Billion53.15%
2015 -A$0.15 Billion46.25%
2014 -A$99.04 Million29.66%
2013 -A$76.39 Million-3530.8%
2012 A$2.22 M-95.73%
2011 A$52.15 M
2009 -A$73.33 Million-45.38%
2008 -A$0.14 Billion-58.87%
2007 -A$0.33 Billion87.3%
2006 -A$0.18 Billion351.97%
2005 -A$38.56 Million-52.09%
2004 -A$80.47 Million-10.98%
2003 -A$90.4 Million
2001 -A$67.48 Million
1999 -A$30.43 Million108.32%
1998 -A$14.61 Million
1996 A$4.45 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
A$32.98 M-96.73%๐Ÿ‡บ๐Ÿ‡ธ USA
A$1.87 B 85.21%๐Ÿ‡ฌ๐Ÿ‡ง UK
-A$46.75 Million-104.63%๐Ÿ‡บ๐Ÿ‡ธ USA
A$15.60 B 1,445.68%๐Ÿ‡บ๐Ÿ‡ธ USA
A$10.86 B 975.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$1.87 Billion-284.56%๐Ÿ‡บ๐Ÿ‡ธ USA
A$54.59 M-94.59%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$64.22 Million-106.36%๐Ÿ‡บ๐Ÿ‡ธ USA